
    slow accrual
  
['cutaneous t-cell non-hodgkin lymphoma', 'recurrent mycosis fungoides and sezary syndrome', 'stage iib mycosis fungoides and sezary syndrome', 'stage iiia mycosis fungoides and sezary syndrome', 'stage iiib mycosis fungoides and sezary syndrome', 'stage iva mycosis fungoides and sezary syndrome', 'stage ivb mycosis fungoides and sezary syndrome']
['fludarabine', 'cyclophosphamide', 'mycophenolate mofetil', 'tacrolimus']

        Inclusion Criteria:

          1. Stage IIB-IV mycosis fungoides and sezary syndrome who have failed at least one
             standard systemic therapy or are not candidates for standard therapy.

          2. Patient should have a responsive skin disease including complete remission (CR) and
             partial remission (PR) (close to CR; 75%-99% clearance of skin disease from baseline
             without new tumors (T3) in patients with T1, T2 or T4 only skin disease) and should
             not have visceral organ or lymph node involvement prior to transplantation.

          3. Patients must have a related donor who is a two or more allele mismatch at the HLA-A;
             B; C; DR and DQ loci. Patients who have sibling donors with a one antigen mismatch due
             to recombination will not be enrolled in this protocol.

          4. Patients must have adequate organ function:

               -  Left Ventricular Ejection Fraction (LVEF) of >50%

               -  Carbon Monoxide Diffusing Capacity (DLCO) >50% of predicted corrected for
                  hemoglobin

               -  Adequate liver function as defined by a serum bilirubin <2.0 (unless hemolysis or
                  Gilbert disease), Aspartate aminotransferase (AST) or Alanine aminotransferase
                  (ALT) < 2.5 X upper limit of normal

               -  Creatinine clearance of > 60 ml/min

          5. Performance status > 80% (Karnofsky)

          6. Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) <5 for age <
             65, HCT-CI <4 for age >65

          7. Patients must be willing to use contraception if they have childbearing potential

          8. Able to give informed consent, or their legally authorized representative can give
             informed consent.

        Exclusion Criteria:

          1. Performance status of < 80% (Karnofsky)

          2. HIV positive

          3. Active involvement of the central nervous system with malignancy

          4. Psychiatric disorder that would preclude patients from signing an informed consent

          5. Pregnancy, or unwillingness to use contraception if they are have childbearing
             potential.

          6. Patients with life expectancy of < 6 months for reasons other than their underlying
             hematologic/oncologic disorder or complications there from.

          7. Patients who have received alemtuzumab within 8 weeks of transplant admission, or who
             have recently received horse or rabbit anti-thymocyte globulin (ATG) and have ATG
             levels of > 2 μgm/ml.

          8. Patients who cannot receive cyclophosphamide

          9. Patients with evidence of another malignancy (exclusive of a skin cancer that requires
             only local treatment);

               -  Patients with prior malignancies diagnosed> 5 years ago without evidence of
                  disease are eligible.

               -  Patients with prior malignancy treated < 5 years ago but have a life expectancy
                  of > 5 years for that malignancy are eligible.

         10. Uncontrolled active infection
      